Title : The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.

Pub. Date : 2020 Apr

PMID : 32129476






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patients with metastatic or locally advanced TNBC with PD-L1 expression on immune cells occupying >=1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab-paclitaxel. nab CD274 molecule Homo sapiens